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I Abstract 
Introduction: While the antiretroviral (ARV) coverage has been scaled- up in the last 3 
years in South Africa, there is limited data on the operating costs and financial sustainabihty 
of an anti- retroviral programme. 
Study Aim: To conduct a cost analysis of the stepdown ARV programme at the 
Kwadukuza Municipality Clinic (KMC) in the Ilembe district from a healthcare providers' 
perspective for the period 1st April 2005 to 31st March2006. 
Study Objectives: To determine the total costs and cost per patient per visit for 
outpatients attending the ARV, Wellness and VCT clinics respectively at KMC. 
Study Methods: 
Study location: This study was conducted at the Kwadukuza Municipality Clinic located 
in the Ilembe district in Kwazulu- Natal, South Africa. 
Study population: 
The population that is included in this study for the purposes of costing comprised: all the 
patients who received ARVs for the period under study; all the patients who attended the 
Wellness and VCT clinics and all the staff attached to the ARV programme at the KMC 
clinic 
Study design: This is a retrospective and cross- sectional study with both a descriptive 
and analytical component. 
Page| 1 
Results: 
Seventy- one percent of the patients on ARVs were female with 50% of the patients being 
between 31 and 40 years of age. The total operating costs of running the ARV programme 
was R2 439 940- 90. 
The total cost accrued to the ARV clinic was R 1 698 003- 60. The Wellness clinic had a 
total cost of R 460 279- 68 and the VCT clinic accounted for the least total operating cost 
of R 281 657-77. 
The cost per patient visit was R440- 13 for the ARV clinic; R133- 05 for the VCT clinic 
and an amount of R61- 71 for the Wellness clinic. 
Conclusion 
This study provides the basis for determining the three cardinal cost components of the 
ARV programme, namely human resources, the cost of ARVs and the costs of viral load 
testing for the purposes of future planning and sustainability. The cost- effectiveness of 
ARV drugs can be improved if the healthcare providers negotiate a lower price for these 
drugs. The high cost due to monitoring tests can be lowered by decreasing the frequency 
of these tests but this may allow ARV drug resistance to be undetected. 
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Chapter 1: Introduction and Background 
1.1 Introduction 
The annual antenatal sero- prevalence survey of pregnant women attending public health 
facilities in South Africa has monitored HIV prevalence since 1990. The data provided by 
these annual surveys estimates the HIV prevalence trends over time in South Africa. The 
national prevalence of HIV positive pregnant women among those attending antenatal 
clinics in 2006 was 29.1%, a decrease from 30.2% in 2005. HIV prevalence varies 
considerably throughout South Africa. Some provinces are more severely affected than 
others, with the highest antenatal prevalence of 39.1% in 2006 in KwaZulu-Natal and the 
lowest of 15.2% in the Western Cape.1 Women account for 55% of People Living with 
HIV and AIDS (PLWHA) in South Africa. The peak age for HIV infection in women is 
25-29 years while for men it is the 30-35 years age group. 
The HIV & AIDS and STD Strategic Plan for the period 2000 - 2005 was launched in 
2000 to provide a strategic framework for the country's response to the HIV & AIDS and 
STD epidemics. The purpose of the plan was to provide a broad national framework 
around four priority areas: prevention; treatment, care and support; research, monitoring 
and evaluation and human and legal rights.2 
The Cabinet decided on a number of measures to strengthen the implementation of the 
HIV & AIDS and STD Strategic Plan in April 2002. Amongst the various measures 
introduced, the commitment from government to remove systemic constraints on access to 
anti- retroviral treatment was the most significant of these measures. 
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The government established a Joint Health and Treasury Task Team (JHTTT) in July 2002 
to investigate issues relating to the financing of an enhanced response to HIV and AIDS. 
A particular focus of the JHTTT was on the second component of the Strategic Plan, 
namely treatment, care and support for those infected and affected by HIV and AIDS. 
Following a review of the report from the JHTTT, the Cabinet instructed the Department 
of Health (DOH) to develop a detailed operational plan on an Anti- retroviral Treatment 
(ART) programme by the end of September 2003.3 
In November 2003, the government approved the Operational Plan for Comprehensive 
HIV and AIDS Care, Management and Treatment for South Africa. Implementation of 
the Comprehensive HIV and AIDS Care, Management and Treatment Plan (CCMT) 
started in the first quarter of the 2004. 
The operational plan aimed to accomplish two interrelated goals: 
• To provide comprehensive care and treatment for PLWHA 
• To facilitate the strengthening of the national health system in South 
Africa.4 
According to the Actuarial Society of South Africa (ASSA) 2000 model, it was estimated 
that by 2009, about 1.4 million people will require antiretroviral (ARV) therapy.5 
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The plan is premised on the following pillars: 
• Ensuring that the great majority of South Africans who are currently not 
infected with HIV remain uninfected. The messages of prevention and of 
changing lifestyle and behavior therefore together constitute the critically 
important starting point in managing the spread of HIV and the impact of 
AIDS. 
• Enhancing efforts in the prophylaxis and treatment of opportunistic 
infections, improved nutrition and lifestyle choices. 
• Effective management of those HIV-infected individuals who have 
developed AIDS-defining illnesses, through appropriate treatment of AIDS-
related conditions (including the possibility of using antiretroviral therapy in 
patients presenting with low CD4 counts to improve functional health status 
and to prolong life), and suitable palliative and terminal care where treatment 
has run its course.4 
The plan proposes an expenditure of R750 million for upgrading systems in healthcare 
infrastructure in areas such as drug distribution, patient information systems and 
pharmaco- vigilance, over R300 million for new capital investments, and over R230 
million for research. The budget estimates indicate that nearly R4.5 billion will be 
required for funding the Comprehensive Care and Treatment plan in 2007/8. This includes 
more than Rl billion for new health professionals; about Rl,6 billion for antiretroviral 
drugs; R800 million for laboratory tests and more than R650 million in additional 
nutritional supplements and support. 
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1.2 Rationale for the study 
The Operational Plan has now entered into its third year of implementation and despite the 
numerous obstacles, continues to grow in strength. The number of patients on ARV 
treatment rose from 41 719 in March 2005 to 213 828 in September 2006. This constitutes 
the fastest growing ARV programme in the world. By the end of December 2006, there 
were 273 accredited ARV sites in South Africa.6 
By March 2007 an estimated 276 995 patients were enrolled for ARV treatment at the 
accredited facilities in South Africa. This represents a six fold increase from the 41 719 
patients enrolled at the end of March 2005 and a two-fold increase from the 141 774 
patients enrolled at the end of March 2006. 
The efficacy of ARVs has been proven in prolonging and improving the quality of life for 
PLWHA, globally. In order for PLWHA to have access to this life- prolonging therapy, 
careful planning is essential. 
1.3 Background to the Kwadukuza Municipality Clinic' ARV programmme 
The first ARV rollout programme in the Ilembe district commenced at Stanger Provincial 
Hospital (SPH) in June 2004. The Kwadukuza Municipality Clinic (KMC) had not 
acquired full accreditation status, however, due to its close proximity to a regional hospital 
it was classified as an extension site of SPH. This primary health care clinic is located in 
an urban setting and is situated approximately 1,5 kilometres away from SPH. The first 
batch of patients on ART were referred down to KMC on the 1st April 2005. 
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The KMC clinic provided a comprehensive package of AIDS services which included 
counselling, support, prophylaxis, treatment of opportunistic infections, provision of ARV 
treatment and referrals to SPH where necessary. 
1.3.1 Patient flow in an ARV programme 
The three components of an ARV programme (ART) are as follows: 
• Voluntary Counselling and testing Clinic (VCT) 
• Wellness Clinic 
• Anti- retroviral (ARV) Clinic 
1.3.1.1 VCT Clinic 
The VCT clinic is the portal of entry into the ARV programme. A client may be referred 
to or voluntarily present themselves for HIV testing at the VCT clinic. On the first visit, 
the client will receive pre- test counselling from a certified VCT counsellor which, on 
average, will last for about 15 minutes. Both the testing with a rapid HIV test kit and 
production of the result of the test will, on average, take another 15 minutes. If the test is 
positive, a confirmatory test will be done. If the client tests positive, post test counselling 
will be provided, that takes an average of 10- 15 minutes. 
1.3.1.2 Wellness Clinic 
The client is then referred to Wellness Clinic to make an appointment. On the first visit, 
the client will be attended to by a nurse who will introduce the client to the concept and 
benefits of the Wellness Clinic. The purpose of a baseline CD4 count test will be 
explained and done during this visit. A cursory clinical history and examination will be 
conducted. This initial consult will take, on average, 15 minutes. 
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If the client is not categorised as WHO Stage 3 or Stage 4 nor is the client moribund 
clinically, then the second visit will be scheduled for a month later. A systematic enquiry 
is made and a short clinical examination is conducted detailing all the important clinical 
parameters (blood pressure/haemoglobinometer reading/ glucometer reading/ 
weight/height/body mass index). The result of the CD4 count is also made known to the 
client. If the client's CD4 is greater than 200, the client will be given prophylactic 
treatment (Co- trimoxazole, MVT) and assessed or reviewed on a monthly basis. If the 
CD4 count is below 200 or the client is deemed to be a WHO Stage 3 or Stage 4 
(irrespective of CD4 count), this client will then be referred to the ARV clinic to be 
enrolled onto the ARV programme. 
1.3.1.3 ARV Clinic 
The clients are given a booking for their first visit. The assembled clients who are eligible 
for ART or who are referred down from another facility will receive group counselling by 
one of the ARV Clinic nurses. Group counselling will occur at each of the monthly visits 
that clients attend. Clients will then be seen individually by the ARV clinic nurse/s. The 
ARV Rollout booklet will have to be completed for patients waiting for ART by the VCT 
counsellor and the ARV clinic nurses in the relevant sections. Pre- ART baseline 
investigations (full blood count/urea and electrolyte/liver function tests/total 
cholesterol/triglyceride level/amylase/acid fast bacillus cytology/ urine dipstix/glucometer 
reading and chest X-Ray) will be done as well as the assessment of the clinical 
parameters. This initial consult may take, on average, 20- 30 minutes. 
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All the results of these investigations will be collated by the ARV clinic nurses. On the 
second visit the assessment will be undertaken by the ARV clinic medical officer, who 
will do a full clinical examination, review all the results and fill in the relevant sections in 
the ARV rollout booklet. This visit will take, on average 15- 20 minutes. If the results of 
all the investigations are favourable, the client will be booked for the Adult Literacy 
Programme which is a 3 day work- shop and constitutes the third visit. 
This work- shop is conducted by the VCT counsellors. The tenets of prevention of HIV, 
adoption of a healthy lifestyle and all the benefits of ART and the potential adverse effects 
of ART will be discussed during these 3 days. On the last day of the work- shop, the client 
will be referred back to the medical officer who will prescribe the relevant ARV regimen 
as chosen by the client. This will take, on average, 3-5 minutes. The relevant section in the 
ARV rollout booklet will also be completed. 
The client is then referred to the pharmacist and data capturer team. The pharmacist 
counsels the client again on ARVs and then duly dispenses the ARVs which, takes on 
average, 10 minutes. The client is then seen by the data capturer who records their clinical 
and socio- demographic profile. This process takes an average of 15 minutes. 
The client is then reviewed by the nurse, pharmacist and data capturer two weeks after 
commencement of ARVs. Problem cases are referred to the medical officer. This is the 
fourth visit. 
Subsequent visits are conducted on a monthly basis. CD4 count and VL testing should be 
done every 6 months. If the client is on Regimen lb, the liver function tests are also done 
on a 6 monthly basis. 
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The patient flow in an ARV programme is a dynamic process and is illustrated in 
Figure 1. 
Figure 1: The patient flow cycle in an ARV programme 
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1.3.2 Physical Infrastructure of ARV programme at Kwadukuza Municipality 
Clinic 
1.3.2.1 VCT Clinic 
The VCT counselors used a single room housed in the main KMC building to provide 
their services which included pre- and post- test counseling. 
1.3.2.2 Wellness Clinic 
This clinic was assigned a tiny room which was originally designed for use as a sluice 
room. Prior to the arrival of the mobile park- home, this room was shared by both the 
Wellness and ARV clinic staff and a further two rooms were allocated for use by the 
doctor and pharmacist attached to the ARV programme. 
1.3.2.3 ARV Clinic 
A four room mobile park- home, sponsored by ARK (a British-based NGO), formed the 
physical location of the ARV clinic for the latter part of the study period. The mobile 
home was delivered to KMC in October of 2005. One room was allocated for use by the 
two part- time doctors on a rotational basis. The three nurses used a single room to attend 
to patients. The third room was jointly used by the pharmacists and the data capturer. The 
fourth room was used by the counselors and also served as a storage facility for nutritional 
supplements. Each room had both electricity and water supply and was fully air-
conditioned. 
1.3.3 Human Resource capacity 
The ARV clinic had a multi- disciplinary team, the details of which are included in the 
section on human resources. (Appendix 1) All the staff directly attached to the ARV clinic 
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were employed by ARX with the exception of the counselors and the nurse at the 
Wellness Clinic were employed by the district. 
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1.3.3.1 Medical Doctors 
The ARV Clinic employed a part- time Level 12 medical officer, who worked 10 hours a 
week. A second level 12 medical officer commenced work in January 2006, also on a part-
time basis. 
1.3.3.2 Nurses 
Three nurses were employed to take care of patients attending the ARV clinic. The 
supervisor of the programme was a Level 7 nurse (Senior Professional Nurse) and was 
employed on a full- time basis and worked 40 hours per week. A Level 4 nurse (Staff 
Nurse) was employed for 40 hours a week. Her duties included management of patient 
files, taking blood samples as well as other tests ordered by the medical officer and 
conducting Pap smears. A Level 3 nurse (Enrolled Nursing Assistant) worked 40 hours 
per week and her duties included handing out patient files, conducting group counseling 
and assisting the medical officer in the consultation with patients. 
The nurses did not have a designated room and were required to share space with the nurse 
of the Wellness Clinic (Level 6 nurse) for the first six months of the ARV programme. 
1.3.3.3 Pharmacist 
A full- time pharmacist worked 40 hours per week and his duties included the dispensing 
of ARVs and formulating monthly time- tables for ARV patient groups. 
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1.3.3.4 Data Capturers 
Three data capturers were employed on a full- time basis and were chiefly responsible for 
capturing all data related to the ARV programme. 
1.3.3.5 Patient Advocates 
There were five part- time patient advocates working 25 hours per week. They served as a 
link between the patients on ARVs in their social setting and the staff at the clinic. They 
conducted individual counseling in patients' homes, traced defaulters and were actively 
involved in monthly support group meetings at the clinic. 
1.3.3.6 Cleaner 
The cleaner, employed by the district worked a total of 12 hours per week in the rooms 
utilized by the ARV programme. 
1.3.3.7 Receptionist 
The receptionist worked 0.5 hours per week for the ARV programme. Patients on ART 
were not required to see the receptionist on subsequent visits. They presented themselves 
directly to the nurses at the ARV clinic to collect their files. An additional 4 hours per 
week was allocated to the receptionist for dealing with patients from the VCT and 
Wellness clinics. 
1.3.3.8 Counsellors 
The seven counselors worked for 40 hours per week and were employed by the district. 
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1.4 Relevance of the Study 
There are very few studies focusing on the cost analysis of ARV programmes at primary 
health care level. Primary health care is the vehicle via which comprehensive and 
affordable healthcare is rendered to the citizens of South Africa. It is the backbone of the 
district health system. The vertical programmes, including the ARV programme that are 
part of a primary health care package needs to be cost- effective in ensuring their 
sustainability. 
A cost analysis of the ARV programme will foster the principles of sound budgeting and 
good accounting principles, thereby enabling the programme managers to determine the 
true cost of providing a given unit of service. In this instance the provision of ART. Such 
an analysis will reveal a better understanding of how the ARV programme is run at 
primary health care level as well as detecting unexpected costs. The results of the cost 
analysis will form the foundation on which intervention programmes may be devised and 
implemented. 
A cost analysis can also provide mechanisms to promote accountability on the part of 
program managers; it can help in priority setting in a resource- constrained setting like 
South Africa and may provide some evidence in assisting policy-makers and donors to 
allocate appropriate resources to the ARV program. Of concern is the paucity of 
information concerning the costs required to manage and run an ARV programme at a 
primary health care level. This can constitute a major problem for policy- makers and 
project and financial managers. 
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There were 72 accredited ARV sites in KZN at the end of 2007 and they were located in 
11 districts. This study focused on the cost analysis of the ARV programme at the KMC 
which is located in an urban area in the Ilembe district. The chosen site for the study is 
where the investigator worked on a part- time basis as a medical officer. This cost analysis 
will assist in providing information which can be utilized in making more informed 
decisions in addressing major capacity and infrastructure constraints. 
1.5 Theoretical Framework 
The objectives of this study have been influenced by the theoretical and conceptual 
framework of the systems approach. The application of a modified systems approach is 
depicted in Figure 1. Inputs include basic personnel, drugs, consumables, equipment, and 
other infrastructure dedicated to support activities or services. 
Process activities comprise those activities and services and may include patient care, staff 
trainings, education campaigns and support services. The coverage of the programme and 
utilization rates constitutes output indicators. This study focused largely on the inputs of 













Figure 2: Relationship between inputs and the production process and the resulting 
output. 
The focus was on all costs that were directly and indirectly associated with providing 
health- care to PLWHA at KMC. This included inputs (human resources, commodities and 
products, drugs, planning and administration, and capital expenses) as well as an output 
(the total number of outpatient visits for the year). 
Costs were calculated using the ingredients, micro-costing approach. This micro- costing 
exercise was done via direct allocation of line-item expenditure of the ARV programme at 
this primary health care clinic. 
1.6 Aim of the Study 
To conduct a cost analysis of the step down anti- retroviral programme at the Kwadukuza 
Municipality Clinic in the Ilembe district from a perspective of the healthcare provider.. 
Page|31 
1.7 Specific Objectives of the Study 
1. To determine the gender and age profile of the patients receiving ARV 
therapy at KMC. 
2. To determine the total costs of the components of the ARV programme 
at KMC. 
3. To determine the cost per visit for outpatients attending: 
- the ARV clinic 
- the Wellness clinic programme 
- the VCT clinic 
4. To make recommendations based on the findings of the study. 
1.8 Operational definitions 
1. Cost Analysis: management science, cost and management accounting 
focusing on the relationships between profit (revenue) and expenditure 
(costs). The cost measurement concentrates on the relationship between (a) 
resources used and procedures (activities), as well as resources used and 
outcome (e.g. services provided or product produced). These types of 
analysis are called cost analysis.9 
2. Direct medical costs: directly traced to a procedure or service with a 
reasonable degree of accuracy and without excessive accounting, e.g. 
salaries, equipment, and supplies.10 
3. Indirect medical costs: are not directly traceable to a procedure or 
service, so the costs associated with indirect departments 
are allocated to patient care departments in order to be assigned to 
procedures, e.g utility consumption, administrative services, depreciation 
on buildings and equipment.10 
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4. Fixed costs: are costs that do not vary with the quantity of output in the 
short run (about one year), e.g. rent, equipment lease payments, some 
wages and salaries. These are costs which vary with time rather than 
quantity." 
5. Variable costs: are costs that vary in direct proportion to volume or 
activity e.g. cost of medical supplies.11 
6. Total Cost: cost of producing a particular quantity of output." 
7. Cost per unit of service: the total cost divided by the output. 
1.9 Structure of the Report 
Chapter 2: 
This chapter includes a review of literature to ascertain the HIV and AIDS expenditure in 
South Africa, a methodological approach to costing ARV programmes and the economic 
evaluation of healthcare interventions was performed. 
Chapter 3: 
This chapter deals with the methodology that has been used for this study and the 
reliability and validity of the data collection tools. 
Chapter 4: 
This chapter presents the important findings of the study. 
Chapter 5: 
This chapter discusses the findings of the study. The limitations of the study are also 
discussed at the conclusion of this chapter. 
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Chapter 6: 
This chapter makes conclusions and gives recommendations to both the Ilembe District 
Health Office and ARK in order to assist in providing solutions to the problems that have 
been identified. 
Chapter 2: Literature Review 
A literature search strategy using the Pubmed and Google databases with the following 
keywords: "HIV/AIDS expenditure in South Africa", "costing ARV programmes" and 
"economic evaluation" was conducted. Citations and references were then reviewed to 
identify any additional relevant studies. 
2.1 HIV and AIDS Expenditure in South Africa 
This section will discuss the theoretical aspect of HIV and AIDS expenditure in South 
Africa. 
There has been a sustained financial commitment from government since 2003. The 
National Treasury has allocated funds to the three social departments (health, education 
and social development) which was compatible with the National Integrated HIV and 
AIDS Plan. This formed the government's integrated response to the epidemic in South 
Africa. The Budget of 2005 allocated a total of R6.6 billion for the integrated response for 
the 2005/6 - 2007/8 period.12 
2.1.1 Health HIV and AIDS Finances and Budgets 
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The CCMT receives three main types of HIV and AIDS-specific fund allocations from the 
health sector. These comprise the budget of the HIV and AIDS Directorate in the National 
Department of Health (arising out of the national equitable share); conditional grants 
(CGs) for HIV and AIDS interventions from the national government to provinces and 
HIV and AIDS specific funds in provincial budgets, also known as the equitable share 
(ES) allocations.9 The latter two categories are two funding channels for health related 
HIV and AIDS interventions delivered at provincial level. Table 1 illustrates the allocation 
of funds to the HIV and AIDS directorate from 2003/4 to 2006/7. 
Table 1: Allocation to the HIV and AIDS spending from 2003/4 to 2006/7 
The specific allocation to the National Department of Health for HIV and AIDS has 
increased from R 326 million in 2004/5 to R 410 million in 2006/7. The Comprehensive 
HIV and AIDS Grant for provinces have increased from R781 million in 2004/5 to Rl, 
567 billion in 2006/7. Provincial departments have also increased their commitments to 
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HIV and AIDS by increasing the equitable share allocation for HIV spending from R374 
million in 2004/5 to R874 million in 2006/7.13 
2.1.2 Provincial allocations for HIV and AIDS 
2.1.2.1 Conditional Grants 
Conditional Grants (CGs) were introduced by the Treasury as a mechanism for funding 
province to deal with the burgeoning epidemic. Thus the CGs for HIV and AIDS serve as 
the financial backbone for provincial multi-sectoral responses to the AIDS epidemic in 
South Africa and is provided on the condition it be spent on services or interventions 
specified by national government. Table 2 indicates the provincial distribution of CGs. 
Spending of the funds is limited to specific areas identified by the national government for 
which the provincial departments have to develop appropriate business plans. In the CG 
spending process the role of the national departments is to provide technical as co-
ordination and programme support to the provincial social service departments. In the 
interim, provinces actually implement the programmes, using the CG funds.13 
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Table 2: Comprehensive HIV and AIDS Conditional Grants allocation to Provinces 
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Table 3 below depicts the Division of Revenue Act (DORA) allocations of the HIV and 
AIDS conditional grants versus the actual transfers to the provinces. In 2004/5, the Free 
State, Limpopo, Mpumalanga and North West received less than the DORA allocation. In 
2005/6 the Free State received an additional allocation of R15 million. In 2006/7, the 
Eastern Cape, Gauteng and Western Cape received additional allocations of R14 million, 
R18 million and R18 million respectively. 
Page|38 
Table 3: Comprehensive HIV and AIDS Conditional Grants allocation versus actual 
transfers to Provinces 
! . ' s » l » 
^ ^ ^ ^ W 2004/5 2004/5 2005/6 2005/6 2006/7 2006/7 
^ra^^H^H 98,970 98,970 159,005 159,005 218,021 232,021 
^ ^ ^ ^ B 69,969 55,476 100,874 115,874 142,265 142,265 
^ ^ ^ ^ ^ ^ ^ B 134,231 134,231 185,048 185,048 252,695 270,195 
^ ^ ^ ^ ^ ^ ^ B 186,348 186,348 251,468 251,468 344,304 344,304 
IHfflllL 77,430 70,983 125,899 125,899 175,861 175,861 
r''-'y,f^i--:-' [>yi 53.840 40.379 81.392 81.392 107.479 107.479 
^ ^ ^ ^ ^ ^ ^ H 31,881 31,881 48,050 48,050 68,603 68,603 
Mm • 70,981 59,161 100,921 100,921 142,316 142,316 
Q £ Q M . 57,962 57,962 82,451 82,451 115,670 133,170 
781,612 735,391 1,135,108 1,150,108 1,567,214 1,616,214 
Source: Division of Revenue Act; 2006, NDOH Annual Report 2005/6/7 
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2.1.3 Donor Funding for HIV and AIDS 
Numerous donors provide financial and administrative support for HIV and AIDS 
interventions. Most of these resources are provided to the Department of Health, and some 
are channelled directly to non-governmental organizations (NGOs) and research 
institutions. Table 4 provides a list of some of the funding as received by the NDOH and 
NGOs.14 
Table 4: Donor funding received by NDOH and NGOs 
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Source: National Treasury- IDASA June 2006: www.dcis.gov.za 
KwaZulu-Natal and the Western Cape received donor funds for HIV and AIDS from the 
Global Fund. The Western Cape Health Department is the principal recipient of the Global 
fund grant of $66,509,558 over a six year period from 1 July 2004 to 30 June 2010. 
The funds are advanced directly to the Western Cape provincial treasury and made 
available to the provincial health department as part of the normal budget process. 
Disbursements are received six monthly from the Global Fund. Expenditure recorded in 
the provincial budget for 2004/5 and 2005/6 were R25 678 000 and R50 293 000-00 
respectively. 
KwaZulu-Natal has received R328 million from the Global Fund for the period 2003 to 
2010. Funding for 2003/4 was received late and was spent mainly in 2004/05 and therefore 
additional funds were only provided in 2005/6. 
2.2 Methodological approach to costing an Antiretrovirai programme 
2.2.1 Cost terms 
The use of the word "cost" connotes many different meanings. Hence the definition of 
common cost terms will be defined below. 
Cost 
Cost can be defined as the amount of expenditure (actual or nominal) incurred on or 
attributable to a particular good or activity (e.g. production or service delivery).9 Cost 
includes two major components: the quantity of resources and the value of these 
resources.9 
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Opportunity Cost 
Opportunity cost measures what a healthcare service provider foregoes when it opts to 
spend money on a particular service.9 In other words, an opportunity cost is a lost 
opportunity to invest the sum in some other venture yielding positive benefits.11 
Incremental versus Marginal Costs 
These terms are often used inter- changeably, however, they differ slightly in meaning. 
Both of these terms are defined as the change in cost related to a change in activity. 
Incremental cost, however, is the additional total cost incurred as a consequence of 
changes in activity whilst marginal cost is the additional cost incurred for producing or 
delivering one extra service.9 
Unit cost or Average cost 
The measurement of costs are usually in total and/or per unit. Unit cost is the cost for one 
unit of service and the total cost is the sum of all costs associated with a particular cost 
object.9 
The unit cost can be calculated by dividing the total cost of a particular cost object by the 
number of units of service provided.9 In other words, the unit cost is the average cost per 
unit of service or the mean cost of a particular type of service, for e.g. the cost per visit or 
cost per case or the cost per day is a unit cost. 
2.2.2 Cost classification systems 
2.2.2.1 Classification based on Traceability 
Direct and Indirect Costs 
The total cost attached to a service includes direct and indirect costs. Direct costs are 
directly linked to the use of particular resources or cost objects and can be traced to the 
cost object in an economically feasible way. Examples of direct cost include labour, 
materials or expenses.9 
A health professional rendering service in treating a patient can be classified as a direct 
labour cost. The direct/ indirect classification is independent of the fixed/ variable 
classification. Direct costs are usually variable costs, but may be fixed costs.9 
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Indirect costs are used to specify non- directly allocable costs. They have no direct 
relationship to the cost object and therefore cannot be traced to the cost object easily or in 
an economically feasible manner.9 Indirect costs may also include labour, materials and 
expenses, e.g. the cost of catering or cleaning in a hospital as well as the cost of a clinical 
audit. 
Overhead cost is an umbrella term for a wide range of items that include cost items like 
accommodation, telephone, support services, marketing and general management. Hence 
overhead cost involves indirect labour, indirect materials and indirect expense costs as 
well as other costs that cannot be traced to the cost object in an economically feasible 
9 
way. 
2.2.2.2 Classification by type of cost behaviour 
This sub- type depends on the behaviour of costs in relation to changes in volume over a 
given time period. 
Variable and fixed costs 
Variable costs change by the volume of total activities, e.g. the number of patients 
treated.9 Some examples of variable costs include drugs, diagnostic services, disposables, 
patient transport and patient food.9 
Fixed costs do not change in total despite wide variation of volume.9 They do not change 
with service output (level of activity) or workload over a period of time (either short- run 
or the time period under consideration). Examples of fixed costs include rent, capital 
expenses and insurance premiums. 
2.2.2.3 Classification by the frequency of expenditures 
Capital cost and recurrent cost 
Capital cost is also known as non- recurrent cost whilst recurrent cost is also called 
revenue cost.9 
Recurrent costs are consumed within a single financial year or accounting year. It can 
include direct costs such as cost of goods, services and expenditures, or overheads such as 
rent, salaries and insurance.9 
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Capital expenses are the costs entailed in acquiring fixed assets. These fixed assets are 
usually expensive and confers economic benefits to the health care provider for more than 
one financial or accounting year. 
2.3 Methods of measurement and evaluation of costs in healthcare programmes 
Costs can be divided into 'patient costs' and 'non- patient or programme costs.' Patient 
costs are related to all costs at the point of delivery such as outpatient visits, drugs and 
laboratory tests. Programme costs, on the other hand, refer to administrative costs that are 
expended at district, provincial or central levels.15 
The gross or macro- costing approach estimates the cost of a programme, for example the 
hospitalization for a patient with pneumonia, by allocating an average tariff. An 
ingredients or micro- costing approach involves direct enumeration and the cost of each 
input that is used in the treatment of a patient.16 
The micro- costing approach details all the items used as well as the measurement of all 
the inputs used in a healthcare intervention. The inputs are identified, quantified and then 
converted into value terms to provide a cost estimate.13 This approach is linked to primary 
data collection in randomized controlled trials or observational research studies. It permits 
analysts and policy-makers to validate the assumptions used, judge whether the estimates 
presented can be applied to the setting and if necessary, change the parameters to replicate 
the analysis for their settings.15 
In a gross costing approach, the cost estimates are based on the aggregated information of 
use of resources. The measurement and valuation of resources is usually blurred by 
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adopting this approach, however, has the distinguishing characteristics of simplicity and 
practicality.15 
2.3.1 Stages of cost calculation 
In the process of cost calculation the following stages are defined: 
1) definition of time horizon and perspective, 
2) selection of cost categories, 
3) identification of units 
4) measuring resource use 
5) valuation of resource use1 
2.3.1.1 Definition of time horizon and perspective 
2.3.1.1.1 Time Horizon 
Costs may vary or differ over a period of time hence economists distinguish between short 
run and long run. This distinction between short run and long run is important for costing 
and pricing decisions as there are several cost items which are fixed costs in the short run, 
however, become variable costs in the long run, e.g. depreciation, maintenance and staff 
costs can be classified as fixed cost in the short run but could be variable costs in the long 
9 
run. 
The time period is dependent on the nature of inputs and production. Short run is the 
observation period in which at least one input is fixed in availability whilst in the long run, 
all inputs are variable.9 A short run can mean 3 months, 6 months or a year but usually less 
than 3-5 years.9 
For practical purposes, a short run denotes one financial year.9 In economic evaluations, 
there is a preference for calculating long run marginal cost as the latter takes the initial 
investment costs (capital expenses plus fixed assets) into account. However, in practice it 
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is difficult to estimate long run marginal cost with reasonable certainty, therefore, short 
run average costs are used as a good proxy for long run marginal costs. 
2.3.1.1.2 Perspective 
The perspective or viewpoint must be determined as it may have implications for the 
design of a study or a trial. It also will indicate whose costs you are interested in 
estimating- costs incurred by the healthcare provider, patients and their carers and society. 
Hence the perspective of a study or economic evaluation should always be explicitly 
stated.17 
A societal approach, which has the broadest perspective, includes cost of resources to the 
health system and the cost of resources to patients. It has the following advantages: 
helps to detect cost shifting between sectors 
takes into account the alternative uses for resources outside the healthcare 
sector 
facilitates policies aimed at maximizing the welfare gains to society or 
minimizing the losses.17 
A healthcare provider's perspective considers the cost of resources to the healthcare 
system. This is a narrow approach and includes all direct healthcare costs and costs of the 
non- governmental organizations, however, direct non- healthcare costs (patient travel and 
time costs) are excluded.18 
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A patient- centered perspective considers costs incurred by the patient and their families in 
the process of seeking and receiving treatment, e.g. travel costs and opportunity cost of 
time spent receiving care and waiting in the clinic.19 
2.3.2 Economies of scale 
Economies of scale can have a significant on the unit cost of a particular service. (Ref) 
Economies of scale can be defined as equivalent to a falling long run average cost 
function.20 Average cost includes the imputed cost of capital or other services provided by 
the healthcare providers. 
There are 3 sources of economies of scale: 
product specific economies (output of one product) 
plant (institute) specific economies (output of one 
plant/institution) 
firm- specific economies (output of a firm' operations)9 
The economy of scale of one product can be enhanced by a greater specialization of labour 
and capital. Moreover, the learning curve effect can also contribute to the product- specific 
economies of scale. The learning curve effect equals amount of inputs divided by the 
resources required to produce the same amount of output is decreasing with time. This in 
essence means that the long run average costs declines with the passage of time due to the 
improvement in technical efficiency.9 
The plant or institute specific economies of scales can be partially explained by the 
savings in capital costs and overhead costs such as maintenance and service repair costs, 
e.g. a unit cost of one hospital episode can be significantly lower in a hospital with an 
85% bed occupancy rate rather than in hospitals with a 45% or 65% bed occupancy rate 
due to the considerably lower fixed cost component.9 
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The firm- specific economies of scale are linked with the overall size of the firm. The 
benefits seen with the firm- specific economies of scale are due to the result of savings in 
marketing and sales and/or raising capital funds and/or the distribution of service delivery 
among different plants, as well as joint management. 
Diseconomies of scale exist when long run average costs are increasing at a higher level of 
output.9 
2.4 Costing studies 
The literature search showed four cost analysis studies of an ARV programme and a 
number of cost- effective analysis studies. 
A cost analysis study was conducted at a South African clinic dedicated to providing 
ARVs in 2006.21 This retrospective study by Harling et al21 was conducted from a 
provider' perspective at a peri- urban clinic. Cost data was compared for two financial 
years. The objectives of the study were to determine the cost per patient- month and cost 
per patient- visit in a clinic dedicated for the provision of ARVs. 
Staff cost, both clinical and non- clinical, contributed a large majority of the total clinic 
costs. The construction of a building for use by the ARV clinic had little impact on the 
overall cost of care. 
The total cost of running the ART clinic rose by 142% from USD 174072 (approximately 
R1044432) in 2004/2005 to USD421872 (approximately R2 531 232) in 2005/2006. The 
largest cost component was that of clinical and managerial staff. The cost per patient visit 
fell by 24%o between the 2 years of observation, from USD54.79 (approximately R328.74) 
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to USD 41.62 (approximately R249.72). The authors concluded that increased economies 
of scale appear to offer cost benefits in the South African ARV roll- out. 
Further afield, a cost analysis study of an ARV programme targeted at adult out- and in-
patients was conducted in Thailand. The average cost per outpatient with ARV therapy 
was 281 USD (approximately Rl 686- 00). The maximum expenditure was for ARV 
drugs. One of the conclusions of the study was that it would be considered to be cost-
effective if generic ARVs were used.22 
A cost analysis study was undertaken in India to calculate estimates of recurrent financial 
costs of the ART programme which was commenced in April 2004. The costing exercise 
was conducted from the perspective of the sources of expenditure which included 
government and a host of NGOs.23 
The annual average per client recurrent cost of the ART programme was R2294- 00. The 
authors concurred that due to economies of scale, certain study cost sites were 
proportionately lower with a higher volume of patients. 
McConnel et al24 conducted a cost analysis study of a rapid- test VCT clinic in KwaZulu-
Natal. This was a retrospective analysis of expenditure and output data with a view to 
calculating the cost per client completing VCT. The economic cost of attending to a 
patient was R707- 00. 
Page|50 
This economic cost per patient decreased by 66% over the year as the expenses remained 
stable but the number of patients increased. The study concluded that the cost of providing 
a VCT service was higher than previously expected but declined with an expanding scale. 
The cost effectiveness studies have indicated in general that the ARV programmes are a 
•ye 
cost effective intervention for South Africa. A study by Badri et al in 2005 showed that 
ARVs can be a cost effective intervention in South Africa. 
Badri et al25 developed a Markov state- transition model (a technique that allows current 
data to be extrapolated into the future in order to predict future costs and future effects) 
to determine estimates of life expectancy and quality adjusted life years (QALYs) gained 
for initiation of therapy with three CD4 count thresholds, namely < 200; 200- 350 and > 
350. The study concluded that therapy is most effective when initiated with a CD4 count 
of >200. Delaying treatment to a CD4 count of < 200 will be the most cost- effective 
option (i.e. the incremental cost per QALY gained is lowest). 
In 2002, Boulle et al26 explored the total cost of a national ARV programme in the public 
sector. Eight scenarios in a resource- constrained health system were designed and the 
cost- effectiveness of each scenario was compared. Their conclusion was that with the 
current resource constraints, it was possible to double the number of people on ARVs if 
there was investment in a limited national antiretroviral (ARV) programme. 
According to the study, the total programme costs for the most cost-effective scenario in 
2007 with 107 000 people on ARVs was estimated to be around R409 million.26 The 
authors recommended the rationing of health services in the public sector if an ARV 
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programme was considered. They considered service capacity and readiness as critical 
issues in scaling up an ARV programme rather than resources. 
A study by Geffen, Nattrass and Raubenheimer27 in 2003 estimated the cost of introducing 
several AIDS- related prevention and treatment progammes in South Africa. This study 
was based on modeling by Johnson and Dorrington (2002). 
The cost components of each intervention were discussed in this context. The study 
revealed that the price paid for ARVs comprises the largest cost of an ARV programme. 
They further deduced that the net benefit to government will be significantly lower than 
the direct costs of providing ARVs as PLWHA who are on treatment will have fewer 
episodes of opportunistic infections and thereby result in a reduction in inpatient care. 
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Chapter 3: Study methods 
This chapter details the site of the study, the study population, the study design and study 
period and the instruments used to capture data. The management and analysis of data is 
discussed and the steps to ensure validity and reliability. 
3.1 Study location 
This study was conducted at the Kwadukuza Municipality Clinic located in the Ilembe 
district in the Kwazulu- Natal province of the Republic of South Africa. 
3.2 Study population 
The population that is included in this study for the purposes of costing comprises: 
• All the patients who received ARVs for the period under study 
• All the patients who attended the Wellness and VCT clinics at this location 
during the study period 
• All the staff attached to the ARV programme at the KMC clinic (includes 
the ARV clinic, Wellness clinic and VCT clinic) 
3.3 Sampling strategy 
A single ARV programme was costed for this study hence no sampling strategy was used. 
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3.4 Study design 
The study was retrospective and cross- sectional with both a descriptive and analytical 
component. 
3.5. Perspective 
This study was undertaken from a provider' perspective with respect to ARK, an NGO, 
and the municipal primary health care clinic, KMC. 
Absolute Return for Kids (ARK) is a British charity working to transform the lives of 
children. Their focus is to prevent orphanhood and vulnerable children through keeping 
their parents alive by making ARVs accessible. 
Kwadukuza Municipality Clinic is part of the district health system in the Ilembe district. 
In April of 2004, ARK offered their assistance both in terms of finance and expertise, to 
the Kwazulu- Natal Department of Health. This private-public partnership was 
responsible for initiating the ARV programme in the Ilembe district in April 2005. 
3.6 Study period 
The period of study was from the 1st April 2005 to 31st March 2006 - this was the debut 
year during which patients on ARV therapy were referred down from SPH to KMC. 
3.7 Data Sources 
Primary data sources: 
A semi- structured interview was conducted with the manager of the Kwadukuza 
Municipality Clinic. (Appendix 2) Non- financial data (output data) and the prevalence 
rate for the Ilembe district was obtained from the District Health Information System. 
Financial data (input data) was obtained from the Basic Accounting System (BAS) and 
Personnel Salary System (PERSAL) via the Provincial Department of Health and ARK 
database in Kwazulu- Natal. 
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3.8 Data collection 
The data was collected by the principal investigator. The accuracy and reliability of the 
data was ensured by double- checking the data for errors or for duplication before 
transcription onto data sheets. 
The data included all input costs (direct and indirect) which were provided by both the 
PDOH and ARK. The following variables were used in this study: 
Input data comprised: 
(i) personnel (medical and non- medical) 
(ii) commodities and products 
(iii) laboratory tests: AIDS- related (CD4 count/viral load) and non- AIDS 
related 
(iv) drugs: ARVs and other medication 
(v) planning and administration 
(vi) capital and equipment expenses 
The output data included: 
• the number of outpatient visits 
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Sources of expenditure: 
Human Resources to run the ARV program 
Drugs: 
The cost of the curative and prophylactic drugs was obtained from PMSC. 
The supply of ARV drugs for the study period had been donated by 
PEPFAR. However, the cost of the ARVs was calculated as per state 
tender pricing. 
Laboratory Tests: 
Laboratory tests cost data was obtained from the laboratory manager of 
SPH. (Appendix 10) CD4 counts and reagents, VL and other biochemical 
tests were calculated as per National Health Laboratory Services (NHLS) 
prices. The NHLS is the provider of laboratory services to the public health 
system. The vacuettes and specimen bottles were not included in the price 
of the test and have been costed separately. 
Commodities and Products: this includes all costs associated with 
outpatient visits to the three components: the ARV, VCT and Wellness 
clinics. 
Buildings and equipment 
Data collection tools: 
Qualitative data: 
The interview with the KMC manager sought to provide information on the infrastructure 
of the clinic, the assignment of staff to the components of the ARV programme ( VCT, 
Wellness Clinic, ARV clinic) and the qualifications of staff. 
Quantitative data: 
Collection of quantitative data was commenced only after express permission was 
obtained from the Ilembe district health manager and the executive officer of ARK. 
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(Appendix 3 and Appendix 4 respectively) Data was collected from the ARK database as 
well as the BAS at the Kwadukuza Municipality Clinic. 
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3.9 Data management 
Qualitative data: 
Informed consent was obtained from the KMC manager before the interview was 
conducted. The interview was recorded in writing by the investigator on the questionnaire 
sheet, designed for the study. The responses of these questionnaires were then transcribed 
and saved to the Microsoft Word 2007. 
Quantitative data: 
The data were recorded on summary sheets designed by the investigator. The quality of 
the data was established by double checking all data entry. These were then transcribed to 
the Microsoft Excel Programme as a summary of the different data components. 
3.10 Data analysis 
All data was entered into an Excel table and analysed using standard accounting 
principles. 
Inputs: 
Personnel: The monthly cost of the medical and non- medical staff was calculated using 
the formula: (hours worked in the ARV programme •*• total hours) x gross monthly 
salary. A scarce skills allowance of 1% of annual gross income was included in salaries of 
the doctors, pharmacists and nurses attached to the ARV programme. This was determined 
for the 12 month period. 
Commodities and Products: This included medical consumables, condoms and 
nutritional supplements. The percentages of the annual number of patient visits to the 
components were calculated relative to the total annual patient load for KMC. The 
monthly costs for these items were then apportioned relative to the KMC total cost to the 
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three programme components and finally calculated. Prices for these items were supplied 
by the medical stores department in the Ilembe municipality. 
Drugs: The monthly usage of both ARV and non- ARV drugs were provided by the SPH 
pharmacy department. The cost of the total monthly expenditure of drugs was then 
calculated according to provincial government tender prices provided by PMSC. 
The cost of ARVs for the period 1st April 2005 to 31st December 2005 and for the period 
1st January 2006 to 31st March 2006 were calculated and then summed up to give the total 
cost of ARVs for the study period. (Appendix 5 and Appendix 6) 
Laboratory Tests: 
The numbers of laboratory tests conducted by the three programme components were 
extracted from daily patient registers. This was then double- checked with the SPH 
laboratory register. Prices for each biochemical test and the specimen bottles were 
obtained from National Laboratory Health Services via the SPH laboratory manager. 
The prices were then compared with the costs of tests at a Durban based- private 
pathology laboratory. There was no significant difference as both the public and private 
laboratories adhered to guidelines from NDOH. The prices of the vacuette needles and the 
reagent for the rapid HIV tests were obtained from a private pharmaceutical company 
which supplies these items to the public health institutions. 
The monthly cost of each laboratory test was calculated by multiplying the monthly 
volume and the unit price. This was done for all relevant tests. The cost of the accessory 
items were also calculated in a similar manner. The total monthly cost for tests done was 
then a summing up of all these components. (Appendix 8) This was then determined. 
Planning and Administration: 
• Utilities, supplies and services: 
The expenditure on utilities (water and electricity) was calculated for the 
ARV programme as a percentage of total annual clinic expenditure and 
then apportioned per area occupied to each component. (Appendix 9) 
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• None of the components of the ARV programme had a telephone line 
extension. A central telephone line at the clinic reception area was used 
mainly for incoming calls. Outside calls could only be made to pre-
programmed departments like the Emergency Medical and Rescue 
Services. 
• Stationery for patient records was provided by the medical stores 
department of the Ilembe district health office. The cost for the three cost 
components was estimated as a percentage of the KMC total annual cost 
for stationery. 
• The costs for municipal waste removal, removal of sharps and other non-
degradable medical waste by Compass waste and sterilizing of medical 
instruments were apportioned and calculated as a percentage of KMC total 
cost. 
• Rental: for the first 6 months of the study, the components of the ARV 
programme utilized 4 rooms which were located within the KMC core 
building. Rental was calculated according to market rate values for the use 
of these rooms, which were fully fitted. 
(Appendix 10) 
Capital Expenses: 
A discounted or amortised factor of capital item expenditure was calculated as follows: 
annual depreciation multiplied by return on investment (opportunity cost) 
[the banker' acceptance rate of 9% was utilized (the repurchase rate of 7% 
for April 2005 to March 2006 plus 2%)1] 
maintenance of 1% of product added 
insurance of 1% of product added 
Buildings: 
The cost of the mobile park- home was provided courtesy of the ARK database and 
accommodated the ARV clinic staff during the latter semester of the study period. The 
1 The repurchase rate was obtained from the South African Reserve Bank website for the 
appropriate study period. An extra two percent was added to give the resultant banker' 
acceptance rate. 
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park home was estimated to have a life- span of 20 years. This was discounted, divided by 
two (the park- home was utilized for 6 months) and allocated to the ARV clinic. 
Equipment: 
Equipment and furniture were also calculated according to their replacement value and 
their relative life- span and the discounted amount then apportioned to the respective cost 
components. This value was also divided by two as the rooms of the park- home were 
furnished and fitted for the latter 6 months of the study period. (Appendix 11 and 
Appendix 12) 
The calculation of costs of all these components were standardized by using the actual 
2005 and 2006 market rate values prices exclusive of VAT. Each resource was calculated 
based on the annual utilization by the patients. 
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Total Costs 
The total cost was calculated as the sum of all the service delivery components: 
outpatient visit costs; laboratory tests conducted and drugs prescribed (both ARVs and 
non- ARV medication). 
Output: 
The annual total numbers of patient visits, both scheduled and unscheduled, were 
extracted from daily clinic records. 
Cost per patient visit 
The cost per patient visit was calculated by a simple division of total costs by the number 
of patients who attended the three programme components. All cost data were measured 
over a period of one year to minimize any potential bias that may have occurred due to 
seasonal variations. 
The cost per patient visit was calculated using the following formula: 
Cost per patient visit = Total cost 
Annual total outpatient visits 
3.11 Assuring the reliability and validity of the data 
3.11.1 Quality of data sources 
The following steps were used to ensure that the data collected was relevant as well as of a 
sufficiently good quality: 
• Data was obtained from primary sources (official clinic records, namely 
registers and monthly statistics forms for KMC which were submitted to 
the district health office) and secondary sources. 
• Data was analysed for completeness 
• Data was cleaned to discard any data that was not usable 
3.11.2 Systematic collection and management of data 
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After obtaining the data from the different sources, the following methods were used to 
collate the data in a systematic manner and to ensure quality control: 
• data was extracted from official records and transferred onto data sheets for 
each month of the study period and inserted into a folder which allowed for 
easy access to data. 
• the data from the interview was directly entered onto the questionnaire 
sheet and later transferred to a Microsoft Excel spreadsheet. 
• data on laboratory tests was elicited from the ARV and Wellness clinic 
daily patient registers and cross- referenced with the data at the Stanger 
Provincial Hospital Laboratory. 
3.12 Ethical approval 
The study received approval from the Research and Bioethics Committee attached to the 
University of Kwazulu- Natal. (Appendix 13) Letter of permission to conduct the study at 
the KMC was given by the Ilembe District Health Office on behalf of the Provincial 
Department of Health. (Appendix 14) 
3.13 Summary 
Table 4 summarizes the methodology of the study in terms of the objectives, respondents, 
data collection methods, the data analysis techniques. 
Table 5: Summary of the methodology of the study 
Objectives 
FVof ile of ARV programme 
at KMC 
Total costs of ARVprogramme 
and unit cost per patient visit 
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Chapter 4.Results 
4.1 Introduction 
The findings of the study are presented with respect to the key objectives of the study, 
namely: a precise ascertainment of the gender and age profile of the patients receiving 
ARV therapy at KMC; a determination of the total costs of the components of the ARV 
programme at KMC; a determination of the cost per patient visit for outpatients attending 
the ARV, Wellness and VCT clinics; 
4.2 Presentation of Data 
4.2.1 Gender and Age Profile of patients attending the ARV Clinic 
The KMC serves a catchment population of approximately 14 000 people. The total 
number of stable patients on ARVs that were referred down from Stanger Provincial 
Hospital to KMC during the study period was 258. 
Table 6 details the gender and age breakdown of this group of patients. 
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Table 6: Demographic profile of patients on ARVs at the Kwadukuza Municipality Clinic 
during 1st April 2005 to 31st March 2006 
Seventy- one percent of the patients on ARVs were female with 50% of the patients being 
between 31 and 40 years of age. There were no patients on ARVs aged less than 20 years 
of age. 
4.2.2 Total costs of the components of the ARV programme 
The total costs of the ARV, VCT and Wellness clinics are illustrated in Table 7. 
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Table 7: The total costs of the components of the Anti- retroviral programme at 
Kwadukuza Municipality Clinic for the period 1st April 2005 to 31st March 2006 
Human Resources 
Doctors (ind. scarce skills) 
Nurses (ind. scarce skills) 
Counsellors 
DataCapturers 
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R151746-92 R1338-71 R27 016-40 
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The sum of R 2 439 940- 90 was the total amount required to finance the first year of the 
ARV programme at KMC. The annual total operating costs for the ARV clinic was 
Rl 698 003- 60. This comprises 70 % of the total operating costs of the ARV programme 
at KMC. The Wellness clinic had a total cost of R 460 279- 68 which was equivalent to 19 
% of total costs required to operate the ARV programme at KMC. The VCT clinic 
accounted for the least total operating cost of R 281 667- 77 which equated to 11% of the 
total cost. 
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4.2.2.1 Proportion of cost components 
The proportion that each component conferred to the ARV programme is illustrated in 
Figure 3. 
11 
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Figure 3: The proportion of each component of the Anti- retroviral Programme at 
Kwadukuza Municipality Clinic for the period 1st April 2005 to 31st March 2006. 
4.2.2.2 Breakdown of cost allocation to each component of the ARV programme 
The annual costs of the different items of expenditure for KMC was further disaggregated 
and assigned to the 3 components. Certain expenses had to be allocated according to the 
total number of patient visits for each of these 3 components. This allocation is detailed 
below in Table 8. 
The personnel listed in the table were solely dedicated to the provision of healthcare to 
PLWHA and an allocation of 100% to the cost components on a proportional basis was 
effected. The annual drug expenditure for the ARV clinic and the Wellness clinics were 
allocated directly to these respective components. 
The rest of the costs were allocated as a proportion of the annual total cost of the items of 
expenditure for KMC. 
Table 8: A breakdown of allocated direct and indirect costs for the components of the 
ARV programme at the Kwadukuza Municipality Clinic for the period 1st April 2005 to 
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4.2.2.3 Distribution of the ARV programme costs across the components 
The ARV clinic accounted for the majority of the programme cost categories of staff, 
drugs, laboratory tests and capital expenses with 69%; 88%; 84% and 86% respectively. 
With the remaining two programme cost categories of commodities and product and 
planning and administration, it was the Wellness Clinic which was the major contributor 
with 67% and 50% respectively. (Figure 4) 
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Components of ARV Programme 
Figure 4: The distribution of the Anti- retroviral programme costs across the 3 
components at KMC for the period 1st April 2005 to 31st March 2006. 
4.2.2.4 Distribution of the ARV programme costs at the Kwadukuza Municipality 
clinic 
The planning and administration cost component accounted for 11% of total costs of the 
ARV programme. Under this component, the main cost driver was total insurance for 
KMC (Table 8) 
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Capital expenses (buildings, furniture and equipment) accounted for only 1% of total costs of the 







Figure 5: Share of programme costs in total cost of ARV programme at the Kwadukuza 
Municipality clinic for the period 1st April 2005 to 31st March 2006 
Drug expenditure accounted for 27% of total costs of the ARV programme whilst staff 
comprised 51% of total costs. 
4.2.2.5 Annual breakdown of Anti-retroviral drug regimens 
From 1st April 2005 to 31st December 2005, the monthly aggregated units of Regimen la 
(d4T; 3TC; EFV) accounted for 82% (1333 units) of the ARVs dispensed and amounted to 
R334 143- 11. Regimen lb (d4T; 3TC; NVP) formed 18% (302) of ARVs dispensed in 
2005 and amounted to R29 375-54. 
From 1st January 2006 to 31st March 2006, 621 units of Regimen la (81%) amounted to 
R169 533- 00. The 149 units of Regimenlb (19%) amounted to R16 018- 99. The total 
cost of ARVs dispensed during the study period amounted to R549 069- 64. (Appendix 5) 
The cost of treatment per patient for 2005 with Regimen la and Regimen lb was R250- 66 
and R97- 27 per month, respectively. In 2006, the monthly cost of Regimen la and for 
Regimen lb increased to R273- 00 and R107- 51 respectively. 
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Table 9: The total number of aggregated units of Regimen la and Regimen lb that were 
dispensed at the ARV clinic at Kwadukuza Municipality Clinic for the period 1st April 
2005 to 31st March 2006 
Reg la 
Reg lb 
















302 R97- 27 R29375- 54 
R107-
149 52 
RS49 069- 64 
4.2.2.6 Share of the programme costs across entities 
Figure 6 indicates the distribution of total costs across the two healthcare providers, 
namely, the Department of Health and ARK. The ARV drugs were donated by The 
President' Emergency Plan for AIDS Relief (PEPFAR) who were in alliance with ARK. 
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Figure 6: A share of the programme costs across the entities for the ARV Programme at 
Kwadukuza Municipality Clinic for the period 1st April 2005 to 31st March 2006 
For the programme costs of laboratory tests, commodities and products and planning and 
administration, 100%) of the costs was borne by the DOH. The NGO, PEPFAR, accounted 
for 83% of overall drug cost for the ARV programme. Sixty- seven percent of the cost for 
human resources was carried by ARK whilst the remaining 33%> of this programme cost 
was allocated to DOH. The DOH contributed 74% towards the cost of capital expenses 
and ARK' burden of cost was 26%. 
4.2.3 Cost per patient per visit for the components of the ARV programme 
Table 10 gives a breakdown of the cost per patient per visit for each of the three 
components of the ARV programme at KMC. 
Table 10: The cost per patient visit for the components of the Anti- retroviral programme 
at the Kwadukuza Municipality Clinic for the period 1st April 2005 to 31st March 2006 
Total cost 
Patient consultations 


















The cost per patient visit was R440- 13 for the ARV clinic; R133- 05 for the VCT clinic 
and an amount of R61- 71 for the Wellness clinic 
Chapter 5 Discussion 
The key findings are discussed from a systems perspective, focusing mainly on the inputs. 
The limitations of the study are discussed at the concluding sections of this chapter. 
Determining the total financial costs of the ARV programme in the first year at KMC was 
important as it set the baseline for determining future costs and also the evaluation of the 
cost and sustainability of the programme. Up until now, many of the costing studies have 
focused on the direct medical cost associated with an ARV programme. 
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The micro- costing study of the ARV programme at KMC is crucial for tracking costs and 
to project costs that will be needed, in the future, by health planners in the district to 
allocate resources appropriately and judiciously. 
The programme was accelerated by the joint efforts of the Ilembe District Health Office 
and ARK. ARK has been involved in ARV programmes in the Western Cape. Their 
provision of technical expertise and experience in this arena has been invaluable in making 
this ARV programme, in accordance with national guidelines, a living reality. 
The Wellness and VCT clinics were in operation at KMC before the introduction of the 
ARV clinic. Eligible patients for ARVs were referred to the ARV clinic at SPH. As a 
consequence, there was a long waiting list at KMC for patients to start ARVs. 
Before the commencement of the ARV clinic, the VCT services and Wellness clinic at 
KMC lacked cohesion. The introduction of the ARV clinic ensured a certain degree of 
integration between the 3 key components of the ARV programme. The full integration 
with the TB clinic, the Prevention of Mother- To- Child programme and the sexually 
transmitted infection clinic has yet to be realized at KMC. 
5.1 Distribution of ARV programme costs 
The main cost drivers, excluding the start- up costs, were staff salaries (51%); the cost of 
ARVs (27%>) and planning and administration (11%) as illustrated in Figure 5. The highest 
cost of any service or programme level activity is usually due to personnel.25 However; it 
should be borne in mind that the high share of the total costs attributed to human resources 
is consistent with the requirements for managing a complex ARV programme. 
5.1.1 Human resources 
The ARV Clinic was run by staff that is skilled and therefore commanded higher salaries. 
The annual cost of human resources for the ARV clinic was six times more than the 
Wellness clinic. This illustrates that it is relatively far more expensive to operate the ARV 
clinic than the Wellness clinic but this should improve with the expansion of the ARV 
programme at KMC. 
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5.1.2 Drugs 
The cost of drugs was the second largest contributor to total cost at 27%. This was 
primarily due to the cost of ARVs. Stavudine, Lamivudine and Nevirapine used in the 
public sector are all generic versions of the original patent formulations and are relatively 
inexpensive for a month's supply - R21-71/R24- 36; R33- 95/R37- 86 and R41- 61/R45-
29 at 2005/2006 prices respectively. (Appendix 5) 
Efavirenz (Stocrin) still retains its patent protection and has no generic equivalent in South 
Africa. The cost per month of Efavirenz at 2005 and 2006 prices is R195- 01/R210- 78 
respectively. As 78% of the patients were on Regimen la (which includes Efavirenz), this 
translates into an enormous cost. 
The monthly cost to treat a patient with Regimen la and Regimen lb was R250- 66 and 
R97- 27 respectively for 2005. In 2006, the cost of Regimen la and Regimen lb increased 
to R273- 00 and R107- 51 respectively. This was consistent with the projections made by 
Cleary et al (2005) in a study conducted at three clinics dedicated to HIV- care in 
Khayelitsha, a township on the outskirts of Cape Town in South Africa.27 .The authors 
found that the cost of R325- 76 per patient per month at a clinic was almost half that of 
treating a patient with ARVs as an outpatient in a hospital. They suggested that the costs 
associated with clinic visits are relatively insignificant in comparison with hospital visits. 
The relatively high costs of ARVs have certain disadvantages as well as advantages. 
The disadvantages attached to the rollout of ARVs are: 
• a potential increase in overall treatment costs. 
• possible 'crowding out' of people with other illnesses. 
• possible increases in new HIV infections due to: 
longer life. 
return to risky behavior. 
However, these negative aspects are outweighed by the benefits that ARVs confer: 
• a potential reduction of hospitalization costs. 
• an increased productivity of the labour force. 
• potential reductions in new HIV infections due to lower viral loads. 
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• an increased stability and longevity of family. 
The future is promising as local manufacturing pharmaceutical companies will be 
producing generic versions of all the ARVs that are used in the public sector. Government 
will be able to get further reduction in ARV prices by negotiating through bulk 
procurement purchasing. This potential cost- saving will reduce the life- time costs of 
treating a patient with ARVs. 
5.1.3 Laboratory tests 
The major cost driver in the ARV clinic was the viral load assay. (Appendix 8) Based on 
public sector costs, the cost of a viral load test (R546- 00) was 14 times that of a CD4 
count test (R38-00). 
The cost of the actual VL test was expensive and definitely puts a strain on the allocated 
facility budget for the ARV programme as the VL test has to be done every 6 months for 
monitoring purposes. The VL test is an excellent test to monitor suppression of the HI 
virus and hence the efficacy of the ARVs and the resultant improvement in a patient's 
clinical status. However, the cost and delay in getting results render it impractical as far as 
cost- effectiveness is concerned. In resource-constrained settings like South Africa, the 
WHO (WHO Guidelines 2002a) view VL testing as optional.29 
5.1.4 Nutrition 
Nutritional supplements were indicated for moribund or malnourished patients. These 
supplements were dispensed according to need irrespective of their nutritional status. A 
dietary assessment, including measuring the body mass index, would ensure that 
supplements be given for medical reasons. This would help to contain costs. 
5.1.5 VCT Clinic services 
The cost per patient visit to the VCT clinic was R133- 63. This is far lower than the R707-
00 (the average rand- dollar exchange rate in 2002- 2003 was approximately 1 USD = R5-
00) that was calculated by McConnel et al24 in their study at a VCT clinic in Kwazulu 
Natal. This may have been due to the small study population (662 clients) as opposed to 
the 2117 patients seen at the VCT clinic at KMC. 
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5.2 Strengths and Limitations of the study 
The strength of this study is that it is one of only a few studies that have focused on the 
ARV programme at a primary health care clinic. Furthermore, the study incorporates the 
costs borne by government and an NGO. Data for the majority of the cost categories were 
from primary sources. 
The limitations of this study are listed below: 
5.2.1 Information Bias 
5.2.1.1 Cost data from clinic 
It is a concern that there is a lack of proper accounting done at facility level. Certain cost 
data was not easily available. Data at KMC was not disaggregated according to the 
different cost components. As a result, certain cost categories had to be apportioned 
relative to the total KMC expenditure. 
5.2.1.2 Lack of computerization of clinic data 
The details of volume (patients, drugs and tests) were not computerized and collection of 
data from hard copies was both cumbersome and potential existed for copying mistakes. 
5.2.1.3 Lack of comparative data 
The costs for the initial year of the ARV programme were only considered. This does not 
allow for cost comparison of services as the programme evolved. 
5.2.1.4 Lack of integrated services 
The costs of the TB and PMTCT programmes have not been included. There has been no 
integration of these vertical programmes with the ARV programme. 
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Chapter 6 Conclusions and Recommendations 
This chapter concludes the report with an overall summary of the key findings of the study. 
6.1 Conclusions 
This study identified the three cardinal cost drivers of the ARV programme, namely 
human resources, the cost of ARVs and the costs of viral load testing. This indicates that 
the total costs attached to the three components in the study are inflated by the treatment 
and monitoring of patients on ARVs. 
The cost of ARVs is clearly a significant factor and the key is for the healthcare providers 
to negotiate lower price of these drugs to improve the cost- effectiveness of ART. 
Improved training of healthcare workers in prescribing ARVs and appropriate 
management of ARV drug stock will lead to a further cost saving. 
The costs of monitoring PLWHA at KMC also accounted for a fair proportion of total 
costs at 11%. The danger in reducing the frequency of these monitoring tests to lower 
costs is that patients who develop resistance to certain ARVs may be undetected and this 
will eventually render ART ineffective. 
The cost of the viral load test has not decreased significantly in either the public or private 
sector. An added problem is the long turn- around time between the time of testing and 
receiving the result. 
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6.2 Recommendations 
1. Health Information System: 
Planning and the decision- making process is dependent on accurate and 
readily available information. Therefore the culture of data- capturing 
needs to be continually re- emphasized. This should preferably be 
conducted by the facility information officer on a monthly basis. The 
capturing of accurate data needs to be stressed. Indicators should be 
discussed with clinic staff every quarter. Staff will soon be able to critically 
analyse these indicators as a group which will serve as a learning tool to 
isolate the strengths and weaknesses of different programmes at the clinic. 
2. Political Commitment: 
Increased political commitment from provincial, district and facility 
managerial structures..Communication must be facilitated between staff at 
facility level and managers at district level. Regular meetings need to be 
convened by representatives of these different stakeholders. 
3. Financial Management Training: 
Managers of the facility and supervisors of the various programmes at 
facility level need to attend courses on basic accounting methods of health 
economics. Most of the managers and supervisors are nurses who have had 
no prior experience in financial management. 
Cost centres and activity based accounting practices should be established 
at district and facility level, with the authorization and mandate being given 
to the respective managers in terms of the Public Finance Management Act. 
This will allow facilities to plan appropriately and allow for more efficient 
utilization of funds. Refresher courses must be conducted annually. This is 
crucial to assisting in making the ARV and other programmes cost 
effective. 
4. Portability of ARV Clinic: 
The ARV rollout must be made accessible to patients at clinics that are 
nearest their home. A mobile portable container unit manned by mobile 
health professional teams with all the necessary resources could be a 
solution. This may enhance adherence and compliance. 
5. Drug Management: 
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There should be central processing of ARVs to reduce the burden on 
existing facilities. 
The introduction of an alternative ARV, namely Tenofovir, has introduced 
a potential cost- saving opportunity. The adverse effect profile of Tenofovir 
is minimal in comparison to Stavudine. Stavudine is relatively inexpensive 
but the substitution of this ARV with Tenofovir will reduce the incidence 
of toxic adverse effects like peripheral neuropathy, lactic acidosis and 
lipodystrophy syndrome. Referral to the district hospital will be also 
reduced, thereby resulting in a cost- saving. 
6. Modified Biochemical Monitoring Schedule: 
Best Practice dictates that viral load testing should be conducted every six 
months to monitor effective suppression of the HIV virus. The long turn 
around time and the relative expense of a Viral Load test is making this 
objective biochemical indicator a cost driver. 
The health system infrastructure needs to be revitalized so that these issues 
can be reduced and ensure that the viral load testing remains in situ. 
However, this will take years rather than months to be effected. 
As an interim measure, the NDOH should adopt the WHO guidelines for 
resource- constrained areas and suggest that viral load testing be conducted 
annually once the patient has achieved viral load suppression. 
7. Donor Funding: 
Donor agencies need to stipulate that a portion of funding be reserved for 
the development of the health system as well as health systems research. 
This in turn will assist in deriving maximum benefit of the ARV 
programme. 
8. Integration of government and non- government initiative 
There must be effective coordination between government and donors to 
improve access to funding at district level. Currently, the ARV programme 
is run jointly by the Ilembe district and ARK. However, funding is still 
occurring in a fragmented manner. Both parties need to disclose full details 
on expenditure so that costs can be minimized, cost duplication can be 
prevented and application made to the provincial department of health for 
an adequate budget allocation. A high level of political commitment for 
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action needs to be shown at all levels of the health system so that 
partnerships with NGOs and other interested parties can be entrenched to 
ensure the viability, sustainabihty and success of the ARV programme.22 
9. Follow- up studies: 
A follow- up cost analysis study should be done at KMC to conduct a 
comparative analysis of cost in accordance with economies of scale. 
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8. Appendices 
8.1 Appendix l:The monthly total cost of personnel of the ARV programme at KMC 
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8.2 Appendix 2: Questionnaire for Clinic supervisor of KMC 
Health facility 
Name of respondent 
Age Gender 
Highest relevant qualification 
Contact details 
Length of service at the present facility 
Length of service as a nurse 
Name of the interviewer 
Date 
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Health facility opening hours (days per week) 
Health facility opening hours (hours per day) 
Are there any specific schedules for seeing ARV therapy patients? 
1. Is this health facility categorized as an urban or a rural health facility? 
a. Urban b. peri-urban c. rural 
2. How many rooms does this facility have? 
a) Totally 
b) Consulting rooms 
3. Do patients need to wait outside the waiting room due to overcrowding in the waiting room? 
4. With regard to infrastructure, does the health facility have a regular supply of electricity? 
a. Yes all the time b. Most of the time c. some of the time 
5. With regard to infrastructure, does the health facility have a regular supply of water? 
a. Yes all the time b. Most of the time c. some of the time 
6. What method does the health facility use to dispose waste material? 
7. What is the catchment population of this health facility (the population the clinic serves)? 
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8. Is security available for your health facility during opening hours? 
9. Is public transport available for patients to get to the health facility? 
10. I'd like to see the patient register for all out patients seen in the general OPD for November 
2005? (The interviewee should count the total number of all patients seen in November 2005 and 
also the number of ARV therapy patients seen per day). 
11. How many clinical staff works in this health facility? (Please indicate the staff diagnose and 
treat patients) 
Enrolled nursing assistants 
Enrolled nurses (staff nurses) 
Professional nurses 
Chief professional nurses 
Senior professional nurses 
Doctors 
VCT counselors 
Other clinic staff 
12. Which clinical staff members and how many of them are involved in the ARV therapy? 
Page|92 
13. How many of the clinical staff is on prolonged leave? (e.g. 1 year study leave) 
14. Are there CHWs and/or HBCVs operating in the catchments area? 
How many CHWs? 
How many HBCVs? 
15. Does the clinic trace defaulters of ARV therapy through 
a. Community Health Workers (CHWs) 
b. Home based Care Volunteers (HBCV) 
c. Any other mechanism? 
16. How many defaulters did you trace last month? 
17. How did you trace the defaulters? 
18. What are the main reasons for defaulting? 
19. Was it difficult to trace defaulters? 
20. Is transport available to the facility for the tracing of defaulters in the communities? 
21. If so, what kind of transport is available? E.g. bicycle, motor bicycle, car. 




23. With regard to laboratory investigations, which lab does the facility refer its samples to? 
24. a. Where do you send patients for x-ray? 
b. How long does it take to get the result? 
25. Does the health facility obtain CD4 counts before the patients next visit? 
26. If not what is the reason for the delay? 
27. How often is the health facility supervised? 
a. monthly b. quarterly c. biannually 
d. annually e. more than a year ago 
29. Is feedback given on the supervision? If yes how long after the supervision? 
30. Who is doing the supervision? 
31. On average how many doses is missed by an ARV therapy patient of his ARV medication in a 
month? 
32. In your opinion, is compliance related to; 
a. gender (if so is it males or females who comply) 
b. socioeconomic status 
c. level of education of the patient 
d. distance from the clinic 
e. Quality of information given by the nurse 
f. Advice of traditional healers 
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g. other reasons, specify 
35. In your opinion what do you think are some of the most important factors that would help 
improve ARV therapy services in the facility? 
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8.3 Letters to relevant authorities 
8.3.1 Appendix 3: Letter to Ilembe district health manager requesting permission to 
conduct study 
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Dr. Y. Kista 




District Health Manager 
Ilembe 
19th June 2006 
Dear Madam 
I want to undertake a Cost Analysis of the Antiretroviral programme at the 
Kwadukuza Clinic. This will be for the completion of my Masters in Public Health 
degree. 
I need written permission from you to be able to complete this task. Your letter will 
be attached to my protocol and submitted to the Ethics committee of the Kwazulu-
Natal University. Permission has also been sought from Dr. Ashraf Grimwood from 
ARK. 
This is purely an academic exercise and a copy of the result will be sent to you 
before submission to the Department of Community Health at the Nelson Mandela 
Medical School. 
Thank you for your co- operation. 
Yours sincerely 
Dr. Y. Kista 
Tel /Fax: (032) - 5514953 
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8.3.2 Appendix 4: Letter to Chief Executive Officer of ARK seeking permission to 
conduct study. 
Dr. Y. Kista 
P.O. Box 4621 
Kwadukuza 
4450 
Dr. Ashraf Grimwood 
Executive Director 
ARK 
Fax N o : 021-4486157 
19th June 2006 
Dear Ashraf 
I will be submitting my protocol to the Ethics Committee for approval. I need to 
have written permission from ARK to undertake my project. 
I would like to reiterate that this is purely an academic exercise for the completion 
of my Masters in Public Health degree. A copy of the report will be sent to you for 
perusal before submission to the Department of Community Health at the Nelson 
Mandela Medical School. 
My supervisor is Professor Indres Moodley and he can be contacted at the 




Dr. Y. Kista 
Tel/Fax - (032) 5514953 
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8.4 Annual drug expenditure for the ARV and Wellness clinics at KMC 
8.4.1: Appendix 5: The total annual cost of drugs used by the ARV and Wellness clinics 





































































































































































































































































































































































































































































































































































































































































































































































8.4.2 Appendix 6: Breakdown of annual non- ARV drug expenditure for the ARV and 
Wellness clinics at KMC for the study period. 
MONTH Wellness Clinic AR\/clinic 
Apr-05 6205-30 12754-70 
May-05 6138-28 24266-14 
Jun-05 5348-52 34072-92 










Nov-05 8236-78 59247-18 







Mar-06 6288-00 65954-68 
fotal(in Rands) 76562-55 584447-19 
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8.5. Annual breakdown of commodities and products utilized by the ARV 
programme at KMC 
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8.5.2 Appendix 8: Breakdown of laboratory tests for the three components for the study 
period at KMC 


































































































































































CD4 * 130 
VL 0 
Heo screen 0 
WR 0 
Pap smear 0 
Preqstat 0 
Vacuettes 130 
Tubes purple 130 
plain 0 
VL 0 















































CD4 * 172 
VL 0 
Hep screen 0 
WR 0 
Pap smear 0 
Preastat 0 
Vacuettes 172 
Tubes purple 172 
plain 0 
VL 0 















































CD4 * 71 
VL 7 
Hep screen 0 
WR 0 
Pap smear 0 
Preqstat 0 
Vacuettes 81 
Tubes purple 71 
plain 3 
VL 7 


















































































































































































































































































































































































































































































































































































































































































































8.6 Appendix 9 :The annual utilities expenditure for the three components of the 
ARV programme at KMC for the study period 
Total covered area of the clinic - Area (Area of building + verandah) + mobile home 
= (912 sq.m + 317.8 sq.m) + 36.74 sq.m 
= 1229.8 sq.m + 36.74 sq.m 
= 1266.54 sq. m 
April 2005 to September 2005: ARV clinic = Room 4 + Wellness clinic + 2 times counsellor rooms +Pharmacist room 
= 12.18 +9.45 + ( 2 * 12.18)+ 12.18 
= 58.17 sq.m 
October 2005 to March 2006 : ARV clinic = Mobile home + Wellness Clinic + 2 times counsellor' rooms 
= 36.74 + 9.45 + 24.36 
= 70.55 sq. m 
Allocated Water and Lights Bill: April 2005 - Sept 2005 = 58.17/1266.54 of total monthly amount 
= 0.046 of total monthly amount 
October 2005 to March 2006 = 70.55/1266.54 of total monthly amount 
= 0.056 of total monthly amount 
Aggregated W&E bi 
MONTH 
II for one quarter (3 months) 
Amount(in rands) Proportion Allocated Amount(in rands) 
ADri| 05 to June 05 12661-37 0.046 582.42 
Julv 05 to Sert 05 13365-38 0.046 614.81 
Oct. 05 to Dec. 05 




















8.7 Appendix 10 : Calculation of rental for the ARV programme at KMC for the first six 
Months 
01/04/05 to 30/09/05 : No capital expenditure. Use made of 4 rooms in the clinic : - Wellness clinic 
Wellness |s clinic/ Nurse1 room 
- Doctor* room 
- Pharmacist'/Data capturer1 room 







Total area of clinic = 1229,8sq. 
(Office space for 2005 in the Kwadukuza area was R45-00 per sq.m) 
m 
Rental of clinic space for period April 2005 to Sept 2006 = 6 times(45.99 times R45.00) =R12417-30 
Rental of mobile home for period October 2005 to March 2006 = 6 times ( 36.74 times R45-001 = R9919-80 
Rent p.m Ann. Rent Semester 
VCTdinic 1 room 12.18sq.m 548-10 6577-20 
Wellness 1 room 9.45sq.m 425-25 5103-00 
ARV Clin 2 rooms 6months (12.18+12.18+9.45) 1521-45 9128-70 4564-35 
36.74 1653-30 9919-80 4959-90 
Clinic ARV VCT Wellness TOTAL 
Tot. Rent 9524-25 6577-20 5103-00 R21204-45 
8.8 
8.8.1 Appendix 11: Inventory of capital expenses for the ARV programme at KMC for 
the study period 
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Inventory of equipment used by the AFW programme at KMCfor the period 1st October 2006 to 31st March 2006 
Oinic Quantity Unit price Lifespan Arm.Amt 
(inR) Value (in years) (biRJ (inR» 
Wellness dinic 
VCT|2 rooms) 

















2 stationery cupboards 
1 computer 
1 printer 
1 label machine 
1 stapler 
1 examination couch 
1 punch 
1 digital scale 
1 stethoscope 
1 diagnostic set 
2 sphygmomanometers 
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BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Nelson R Mandela School of Medicine 
Private Bag 7, Congella 4013 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 
Fax; 27 31 2604609 
Email: buccas@ukzn.ac.za 
Website: www.ukzn.ac.za 
22 December 2006 
Dr. Y. Kista 
Department of Community Health 
P 0 Box 4621 
KWADUKUZA 
4450 
Dear Dr. Kista 
PROTOCOL: A Cost Analysis of the Antiretroviral Programme at the Kwadukuza 
Clinic in the llembe District. Dr. Yogendiran Kista. Dept. of Community Health. 
Ref: EXP055/06 
EXPEDITED APPLICATION 
Dear Dr. Kista 
This letter serves to notify you that at a full sitting of the Biomedical Research 
Ethics Committee meeting held on 12 December 2006, the Committee RATIFIED the 
sub-committee's decision to approve the above study. 
Yours sincerely 
SURAIYA BUCCAS 
Ethics Research Administrator 
SB/sn 
8.10 Appendix 14: Authorization from Department of Health 
77 Hulett Street, Stanger, 4450 
Private Bag X 10620, Kwa Dukuza, 4450 





Reference : DM/06/06/1477 
Enquiries : Miss S. Dube 
Telephone : 032-4373500 
2 1 S T June 2006 
Dr Y. Kista 
P.O. Box 4621 
Kwadukuza 
4450 
Re : Cost Analysis of the Antiretroviral Programme 
Your letter dated 19th June 2006 has reference. 
Permission to conduct research in the Department's service outlets is given by the HOD. 
Previous experience has taught us that the Ethics Committee should first give its 
written approval to conduct the research which must then accompany your request to 
the Department. 
You are therefore advised to resubmit your request with the Ethical Committee's 
approval to this office for onward transmission. 
Wishing you all the best in your study. 
Yours sincerely 
ft 
is S. Dube 
District Manager 
llembe Health District 
uWInyango Wezempilo . Departement van Gesondheid 
Fighting Disease, Fighting Poverty, Giving Hope 
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